This software bot accelerates and streamlines the scheduling of hundreds of thousands of patient appointments to receive the two-shot vaccine for COVID-19.
Clalit Health Services, the largest healthcare maintenance organization in Israel, has already used the Kryon V-Bot to schedule more than 100,000 vaccine appointments per day.
Israel leads the world in COVID vaccinations and having already vaccinated 30% of its eight m citizens.
The logistical problems facing healthcare organizations attempting a controlled COVID-19 vaccine roll-out are astounding.
Many hospitals, healthcare providers and HMOs receive vaccines with little notice, placing enormous stress on support staff to schedule last minute appointments and use every available dose.
By automating scheduling based on eligibility criteria, the burden is lifted allowing them to focus on areas that require a human touch, like patient care and service.
Kryon is offering the V-Bot to all healthcare providers to expedite the required double-appointment setting. The purchase of Kryon V-Bot includes an unlimited amount of software bots to assist in the mass scheduling.
Further, Kryon will also customize the automation workflow of an organization's patient scheduling process based on an individual organization's structure and needs.
Kryon is in enterprise automation, offering the only platform on the market which encompasses both Process Discovery technology and Robotic Process Automation (RPA).
The Kryon Full-Cycle Automation solution maximizes ROI by 352% according to Forrester Research and cuts RPA implementation time by up to 80%.
Powered by proprietary AI technology, Kryon Process Discovery automatically generates a comprehensive picture of business processes, evaluates them, and recommends which ones to automate.
Kryon offers desktop-based attended RPA, virtual-machine-based unattended RPA, or a hybrid combination of both. The company's award-winning suite is used by enterprises worldwide, including AIG, Allianz, Deutsche Telekom, EY, Ferring Pharmaceuticals, HP, Microsoft, Santander Bank, Singtel, Verizon, and Wyndham Hotel Group.
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Micron Biomedical names new scientific advisor to CEO
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences